Latest News

FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC

October 16th 2024

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in patients with metastatic non–small cell lung cancer.

FDA Approves Perioperative Nivolumab in Resectable NSCLC
FDA Approves Perioperative Nivolumab in Resectable NSCLC

October 3rd 2024

SABR and Hypofractionated Chemoradiation Improves Lung Cancer Outcomes
SABR and Hypofractionated Chemoradiation Improves Lung Cancer Outcomes

September 30th 2024

Five-Year Data Shows CheckMate 9LA Regimen Maintains Survival in NSCLC
Five-Year Data Shows CheckMate 9LA Regimen Maintains Survival in NSCLC

September 24th 2024

BAY 2927088 Shows Promise in HER2-Mutant NSCLC
BAY 2927088 Shows Promise in HER2-Mutant NSCLC

September 20th 2024

More News